[ad_1]
“The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within anticipated timelines,” Aurobindo Pharma said in a regulatory filing.
In September 2018, Aurobindo Pharma had said its US subsidiary has entered into a pact to acquire commercial operations and three manufacturing facilities in America from Sandoz Inc, USA, for USD 900 million.
The acquisition was to be made through its wholly-owned subsidiary, Aurobindo Pharma USA Inc.
The transaction if completed would have positioned the Hyderabad-based firm as the second largest dermatology player and the second largest generics company in the US by prescriptions.
[ad_2]
Source link